Type 1 diabetes is treated with insulin replacement, because the immune system has destroyed the cells in the pancreas that produce it. There is no alternative to insulin for type 1 diabetes, and treatment is lifelong. But the tools available today, from continuous glucose monitors to automated insulin pumps, make it far more manageable than it was even a decade ago.
How Insulin Therapy Works
Everyone with type 1 diabetes needs insulin, but the specific regimen varies. The goal is to mimic what a healthy pancreas does naturally: release a steady background level of insulin throughout the day and surge extra insulin when you eat. Most treatment plans combine two types of insulin to accomplish this.
Long-acting insulin provides that background coverage. It starts working about 2 hours after injection, has no sharp peak, and lasts up to 24 hours. You typically take it once or twice a day at roughly the same time. Rapid-acting insulin covers meals. It kicks in within 15 minutes, peaks around 1 hour, and wears off in 2 to 4 hours. You take it just before eating, and the dose depends on how many carbohydrates are in the meal.
This combination, often called multiple daily injections (MDI), usually means 4 or more shots per day. The alternative is an insulin pump, which delivers rapid-acting insulin continuously through a small tube inserted under the skin. Pumps replace the need for long-acting insulin by providing a programmable background rate, then letting you dial up extra doses at mealtimes with the push of a button.
Pumps vs. Injections
Pump users tend to achieve better blood sugar control. In one study comparing the two approaches using continuous glucose monitoring data, pump users had an estimated average HbA1c of 6.9% compared to 7.5% for those on injections. About 53% of pump users reached an HbA1c below 7.5%, versus 33% of injection users. Interestingly, the rate of low blood sugar episodes was similar between the two groups, meaning pumps improved control without adding extra risk of dangerous lows.
Counting Carbs and Calculating Doses
Carbohydrate counting is a core skill because carbs are the nutrient that raises blood sugar the most. Before each meal, you estimate the grams of carbohydrate on your plate, then use your personal insulin-to-carb ratio to figure out how many units of rapid-acting insulin to take.
Your care team will help you find your ratio, but the math behind it is straightforward. The “Rule of 500” divides 500 by your total daily insulin dose. If you use 50 units a day total, the result is 10, meaning 1 unit of insulin covers about 10 grams of carbohydrate. A similar formula, the “Rule of 1800,” calculates your correction factor: 1800 divided by your total daily dose tells you how much 1 unit of insulin will lower your blood sugar. Using the same example, 1 unit would drop your glucose by about 36 mg/dL. These are starting points. You’ll fine-tune them over time based on how your body actually responds.
Monitoring Blood Sugar
You can’t dose insulin accurately without knowing your blood sugar. Traditional fingerstick meters still work, but continuous glucose monitors (CGMs) have become the standard tool. A CGM uses a tiny sensor inserted just under the skin, typically on the arm or abdomen, that reads glucose levels every few minutes and sends the data to your phone or a receiver. It shows not just your current number but a trend arrow telling you whether you’re rising, falling, or stable.
The key metric from a CGM is called Time in Range: the percentage of the day your glucose stays between 70 and 180 mg/dL. International guidelines recommend aiming for at least 70% Time in Range, which works out to roughly 17 hours a day. Equally important is minimizing time below 70 mg/dL (the threshold for low blood sugar) to less than 4% of the day, or under 1 hour total. Time spent above 250 mg/dL should stay under 5%, about 1 hour and 12 minutes.
For older adults or people at higher risk from low blood sugar, the targets are adjusted. Time in Range above 50% and time below range under 1% are considered acceptable.
Automated Insulin Delivery Systems
The biggest leap in type 1 diabetes technology is the hybrid closed-loop system, sometimes called an “artificial pancreas.” These systems connect a CGM to an insulin pump through a software algorithm. The algorithm reads your glucose level in real time and automatically adjusts the background insulin delivery, increasing it when glucose is trending up and reducing or suspending it when glucose is dropping.
The “hybrid” label means you still need to enter your carbohydrate count and approve a dose at mealtimes. The system handles everything else. Currently approved systems include the Medtronic MiniMed 780G, the Tandem Control-IQ, and the Omnipod 5. People using these systems generally spend more time in their target range with less effort than those manually adjusting their own pump or injection doses.
Exercise and Blood Sugar
Physical activity is healthy for people with type 1 diabetes, but it adds a layer of planning because exercise can cause blood sugar to drop quickly. Check your glucose before starting. If it’s between 90 and 124 mg/dL, eat about 10 grams of fast-acting carbohydrate (a few glucose tablets, for instance) before you begin. If it’s between 126 and 180 mg/dL, you’re generally fine to start without a snack.
For longer or more intense sessions, a pre-exercise snack of 15 to 30 grams of carbohydrate (fruit, crackers, or juice) helps prevent a drop. Many people also reduce their mealtime insulin dose before exercise or lower their pump’s background rate. The effect of exercise on blood sugar can last for hours afterward, so checking again after your workout matters too.
Handling Low Blood Sugar
Hypoglycemia, a blood sugar below 70 mg/dL, is the most common acute risk of insulin therapy. Symptoms include shakiness, sweating, confusion, irritability, and a fast heartbeat. The standard treatment follows the 15-15 rule: eat or drink 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 ounces of juice, or a tablespoon of sugar), wait 15 minutes, then recheck. If your blood sugar is still below 70, repeat. Once it’s back in range, follow up with a balanced snack that includes protein to keep it stable. Young children typically need less than 15 grams per round.
Severe low blood sugar, where you can’t treat yourself, requires someone else to administer glucagon, a hormone that rapidly raises blood sugar. Glucagon is available as an injection kit or a nasal spray, and anyone who lives with or cares for a person with type 1 diabetes should know where it’s kept and how to use it.
Recognizing Diabetic Ketoacidosis
When the body has too little insulin, it starts breaking down fat for energy and produces acids called ketones. This can escalate into diabetic ketoacidosis (DKA), a life-threatening emergency. DKA is most common at diagnosis, but it can happen anytime insulin delivery is interrupted, whether from a missed dose, a pump malfunction, or illness.
Warning signs include nausea, vomiting, abdominal pain, fruity-smelling breath, rapid breathing, and extreme thirst. DKA is defined by a blood pH below 7.3 and elevated blood ketone levels (above 3 mmol/L typically signals the need for emergency treatment). If you suspect DKA, it requires immediate hospital care.
Newer Treatment Options
For people at high risk of developing type 1 diabetes but who haven’t yet needed insulin, a treatment called teplizumab can delay the disease. It works by calming the immune attack on insulin-producing cells. In clinical trials, people who received the treatment reached the stage of needing insulin at a median of 50 months, compared to 25 months with a placebo, roughly a two-year delay. The FDA approved it for people aged 8 and older who are in the early autoimmune stages of the disease, identified through blood tests for diabetes-related antibodies.
For adults with severe, hard-to-manage type 1 diabetes, islet cell transplantation is another option. The FDA-approved product Lantidra involves transplanting insulin-producing cells from a donor pancreas. It’s reserved for people who experience repeated episodes of severe hypoglycemia despite intensive management. In clinical studies of 30 patients, 25 achieved some period of insulin independence. Nine of those 25 remained insulin-free for more than 5 years, while 12 were insulin-independent for 1 to 5 years. The trade-off is the need for lifelong immunosuppressive medications to prevent rejection of the transplanted cells.